RBC analyst Michael J. Yee reports, that this is significantly lower when compared to Gilead's Sovaldi week 1 NRx of 151 and Harvoni week 1 NRx of 444. AbbVie's Viekira Pak's week 1 launch is more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results